The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs... Qual Life Res (2017) 26:2479–2488 DOI 10.1007/s11136-017-1574-9 The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries 1,2 2 3 2,4 • • • • Sarah Kleijnen Teresa Leonardo Alves Kim Meijboom Iga Lipska 2 2 1,2 • • Anthonius De Boer Hubertus G. Leufkens Wim G. Goettsch Accepted: 4 April 2017 / Published online: 11 April 2017 The Author(s) 2017. This article is an open access publication Abstract assessments. Developing and implementing into REAs Purpose The aim of this study is to investigate the role of specific evidence requirements for QoL data would health-related quality-of-life (QoL) data in relative effec- improve the use of this patient-centred outcome in future tiveness assessments (REAs) of new anti-cancer drugs reimbursement and pricing decisions. across European jurisdictions, during health technology assessment procedures. Keywords Comparative effectiveness  Quality of life Methods Comparative analysis of guidelines and publicly Health technology assessment  Reimbursement available REAs in six European jurisdictions of anti-cancer Antineoplastic agents  Patient-centred outcome research drugs approved by EMA between 2011 and 2013. Results Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a Introduction relevant endpoint to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Quality of Life Research Springer Journals

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries

Loading next page...
 
/lp/springer_journal/the-impact-of-quality-of-life-data-in-relative-effectiveness-r5K0KYLOjw
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Quality of Life Research; Sociology, general; Public Health; Quality of Life Research
ISSN
0962-9343
eISSN
1573-2649
D.O.I.
10.1007/s11136-017-1574-9
Publisher site
See Article on Publisher Site

Abstract

Qual Life Res (2017) 26:2479–2488 DOI 10.1007/s11136-017-1574-9 The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries 1,2 2 3 2,4 • • • • Sarah Kleijnen Teresa Leonardo Alves Kim Meijboom Iga Lipska 2 2 1,2 • • Anthonius De Boer Hubertus G. Leufkens Wim G. Goettsch Accepted: 4 April 2017 / Published online: 11 April 2017 The Author(s) 2017. This article is an open access publication Abstract assessments. Developing and implementing into REAs Purpose The aim of this study is to investigate the role of specific evidence requirements for QoL data would health-related quality-of-life (QoL) data in relative effec- improve the use of this patient-centred outcome in future tiveness assessments (REAs) of new anti-cancer drugs reimbursement and pricing decisions. across European jurisdictions, during health technology assessment procedures. Keywords Comparative effectiveness  Quality of life Methods Comparative analysis of guidelines and publicly Health technology assessment  Reimbursement available REAs in six European jurisdictions of anti-cancer Antineoplastic agents  Patient-centred outcome research drugs approved by EMA between 2011 and 2013. Results Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a Introduction relevant endpoint to

Journal

Quality of Life ResearchSpringer Journals

Published: Apr 11, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off